中日友好医院辟谣：瑞德西韦临床试验结果未出
针对互联网上流传的抗病毒药物瑞德西韦在武汉“显效”的传闻，正在武汉负责该药物临床试验的中日友好医院副院长曹彬教授今晚对中国青年报·中国青年网记者表示，这一说法不实。
2月5日下午，中日友好医院王辰、曹彬团队在武汉市金银潭医院宣布启动瑞德西韦治疗新型冠状病毒感染的临床研究。瑞德西韦是美国一款处于研发阶段的药物，作用尚有待验证，也未在任何国家上市。
据悉，临床试验的入组患者共计761例，其中轻、中症患者308例，重症患者453例。研究将执行随机双盲试验，以评价药物的有效性和安全性。今天，互联网上关于这一药物短时间内已在761位患者身上“全部显效”的说法甚多。曹彬在回答记者询问时说：“临床研究今天才开始，怎么可能知道结果？”他强调，科学研究需要时间。
此前，中日友好医院曾对外介绍，这项临床研究计划的结束时间是4月27日。 —————————— 为啥要转这样一篇文章？ 我确实对资本炒作医药感到担心。 美国是医药技术最发达的国家， 人均花销在医疗保健上的费用全世界领先， 可是美国的健康水平实在没发让人骄傲。 人均预期寿命竟然不超过被封锁60年的古巴。 而此文之药来自美国一家以资本炒作为主的医药公司。 也就是自己不怎么研发产品， 靠资本炒作收购别人的科研成果进行包装。 当然，临床试验本身也耗资巨大，没有资本炒作者的参与美国是弄不出一个药的。 美国严格的认证流程其好处必须承认，但副作用是没有资本， 有药也没法上市。
文中提到的这个抗病毒药是埃博拉病毒药， 临床有一定效果，但是效果不是最好， 并且埃博拉病毒发病率不高， 所以抗埃博拉病毒药恐怕只能靠政府采购。 抗冠状病毒乃是其副业， 还没有经过验证就被吹成神药， 有些王八蛋们竟然把这个破药和习胖子是否露面联系起来。 这些脑残也不想想， 哪个国家领导人出行不会对病毒严加防范， 病毒并没有那么神奇， 医生被感染多数都在警惕性松懈的时候。 领导然不能随便去疫区并不是怕病毒， 而是去疫区会消耗疫区本来紧张的医疗资源。 影帝温家宝去汶川现场，为了给他摆拍，救人的军人工人还不是浪费宝贵的救人时间， 听他闲扯“一定要， 巴拉巴拉” 药物还没有到的时候网上就流传出所谓神药有多神奇， 可是这些混账也没想想， 双盲试验如果接受实验者各个瞬间好转， 那是证明神药有效，还是证明神药是狗皮膏药？ 这种炒作让我们感觉到了资本的血腥味。
—————————— 维基百科上查了一下该公司的发展过程，看看其资本操作的记录，懒得整理，将就看。 也许与其他高科技公司类似吧， 但是我并没有说其他医药公司不炒作呀。 美国多数科技公司都这样。 因为大公司有大公司综合症导致整体效率下降， 管理者更看重股票的涨跌而不是真正的研发。 公关能力绝对一流。 柳传志把倪光南赶走就是同一个思路， 可惜柳传志没学会公关或者公关没学到位。
In March 1999, Gilead acquired NeXstar Pharmaceuticals of Boulder, Colorado
following two years of negotiations with the company. At the time,
NeXstar's annual sales of $130 million was three times Gilead's sales.
NeXstar's two revenue-generating drugs were AmBisome, an injectable
fungal treatment, and DaunoXome, an oncology drug taken by HIV patients. Also in 1999, Roche announced first approval of Tamiflu (oseltamivir) for the treatment of influenza. Tamiflu was originally discovered by Gilead and licensed to Roche for late-phase development and marketing. Viread (tenofovir) achieved first approval in 2001 for the treatment of HIV. 2000 to 2009In 2002 Gilead changed its corporate strategy to focus only on antivirals, and sold its cancer assets to OSI Pharmaceuticals for $200 million.[12] In December 2002, Gilead and Triangle Pharmaceuticals announced
that Gilead would acquire Triangle for around $464 million; Triangle's
lead drug was emtricitabine that was near FDA approval, and it had two other antivirals in its pipeline.[12][13] The company also announced its first full year of profitability. Later that year Hepsera (adefovir) was approved for the treatment of chronic hepatitis B, and Emtriva (emtricitabine) for the treatment of HIV. In 2004, Gilead launched Truvada. Years later, though efforts of
activists and other groups, Gilead was convinced that a fixed-dose
combination of tenofovir and emtricitabine could be used as a pre-exposure prophylactic against the transmission of HIV. [14] In 2006, Gilead completed two acquisitions that allowed the
company to branch out from its historical antiviral franchise into the cardiovascular and respiratory therapeutic arenas. Under an agreement with GlaxoSmithKline, Myogen marketed Flolan (epoprostenol sodium) in the United States for the treatment of primary pulmonary hypertension. Additionally, Myogen was developing (in Phase 3 studies) darusentan,[15] also an endothelin receptor antagonist, for the potential treatment of resistant hypertension. In 2006, the company acquired Corus Pharma, Inc. for $365
million. The acquisition of Corus signaled Gilead's entry into the
respiratory arena. Corus was developing aztreonam lysine for the
treatment of patients with cystic fibrosis who are infected with Pseudomonas aeruginosa. In July 2006, the U.S. Food and Drug Administration (FDA) approved Atripla, a once a day single tablet regimen for HIV, combining Sustiva (efavirenz), a Bristol-Myers Squibb product, and Truvada (emtricitabine and tenofovir disoproxil), a Gilead product.[16][17] Gilead purchased Raylo Chemicals, Inc. in November 2006 for a price of $133.3 million.[18] Raylo Chemical, based in Edmonton, Alberta, was a wholly owned subsidiary of Degussa AG,
a German company. Raylo Chemical was a custom manufacturer of active
pharmaceutical ingredients and advanced intermediates for the
pharmaceutical and biopharmaceutical industries. Later in the same year
Gilead acquired Myogen, Inc. for $2.5 billion (then its largest
acquisition). With two drugs in development (ambrisentan and
darusentan), and one marketed product (Flolan) for pulmonary diseases,
the acquisition of Myogen has solidified Gilead's position in this
therapeutic arena. Gilead expanded its move into respiratory therapeutics in 2007 by entering into a licensing agreement with Parion for an epithelial sodium channel inhibitor for the treatment of pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disease and bronchiectasis.[19] In 2009, the company acquired CV Therapeutics, Inc. for $1.4
billion, bringing Ranexa and Lexiscan into Gilead. Ranexa is a
cardiovascular drug used to treat chest pain related to coronary artery
disease, with both of these products and pipeline building out Gilead's
cardiovascular franchise.[20] Later, in the same year the company received the award for one of the Fastest Growing Companies by Fortune. In the same year they were also named as one America's Top Companies to work for by Forbes. 2010 to 2019In
2010, the company acquired CGI Pharmaceuticals for $120 million,
expanding Gilead's research expertise into kinase biology and chemistry.
Later that year, the company acquired Arresto Biosciences, Inc. for
$225 million, obtaining developmental-stage research for treating
fibrotic diseases and cancer.[21] In 2011, the company acquired Calistoga Pharmaceuticals for $375
million ($225 million plus milestone payments). The acquisition boosted
Gilead's oncology and inflammation areas.[22] Later that year, Gilead made its most important acquisition — and most expensive to date — with the $10.4 billion purchase of Pharmasset, Inc. This transaction helped cement Gilead as the leader in treatment of the hepatitis C virus by giving it control of sofosbuvir (see below). On July 16, 2012, the FDA approved Gilead's Truvada for prevention of HIV infection (it was already approved for treating HIV). The pill was a preventive measure (PrEP) for people at high risk of getting HIV through sexual activity.[23] In 2013, the company acquired YM Biosciences, Inc. for $510 million. The acquisition brings drug candidate CYT387, an orally-administered, once-daily, selective inhibitor of the Janus kinase
(JAK) family, specifically JAK1 and JAK2, into Gilead's oncology
pipeline. The JAK enzymes have been implicated in myeloproliferative
diseases, inflammatory disorders, and certain cancers. In 2015, the company made a trio of acquisitions: It bought Phenex Pharmaceuticals for $470 million. Its Farnesoid
X Receptor (FXR) program used small-molecule FXR agonists in the
treatment of liver diseases such as nonalcoholic steatohepatitis.[24] It bought EpiTherapeutics for $65 million. This acquisition gave Gilead first-in-class small molecule inhibitors of histone demethylases involved in regulating gene transcription in cancer.[25] It paid $425 million for a 15% equity stake in Galapagos NV, with
additional payments for Gilead to license the experimental
anti-inflammatory drug filgotinib, which may treat rheumatoid arthritis, ulcerative colitis, and Crohn's disease.[26]
In 2016, the company acquired Nimbus Apollo, Inc. for $400 million,
giving Gilead control of the compound NDI-010976 (an ACC inhibitor) and
other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis and for the potential treatment of hepatocellular carcinoma.[27][28] Also in 2016, the company was named the most generous company on the 2016 Fortune list of The Most Generous Companies of the Fortune 500. Charitable donations to HIV/AIDS and liver disease organizations totaled over 440 million in 2015.[29] In August 2017, the company announced it would acquire Kite Pharma for $11.9 billion,[30] equating to $180 cash per share, a 29% premium over the closing price of the shares. The deal will add the promising CAR-T candidate to the companys existing portfolio.[31]
In November, the company announced it will acquire Cell Design Labs for
up to $567 million, after it indirectly acquired a stake of 12.2% via
the Kite Pharma deal.[32] On May 9, 2019, the U.S. Department of Health and Human Services
announced that Gilead Sciences will donate Truvada, the only drug
approved to prevent infection with H.I.V., for free to 200,000 patients
annually for 11 years. [33]
On December 3, 2019, HHS explained how the government would distribute
the donated drugs. The new program called Ready, Set, PrEP is accepting
applications from any patient who doesn't have health insurance, has a
valid prescription for PrEP and has had a recent negative H.I.V. test.
To apply, patients can call 855-477-8410, online at www.getyourprep.com
or in person at participating health care provider. HHS Secretary Alex
Azar explained that the U.S. government will pay Gilead $200 per bottle
for 30 pills for costs associated with getting the drug from factories
into the eventual hands of patients.[34]
|
